Current Highlight from June 26, 2015
miRNA Regulation as a Biomarker of Carcinogenicity
Scientists from FDA's NCTR, Dalian Medical University (China), and Universidad de Granada (Spain) utilized an integrated approach to assess the utility of miRNA regulation as a marker of carcinogenicity. Kidney samples from rats treated orally with a carcinogenic dose of aristolochic acid (an IARC Group I carcinogen and known rat kidney carcinogen) were analyzed for miRNA and mRNA expression using deep sequencing and protein expression using proteomics. The analyses identified 63 miRNAs that were dysregulated in response to AA, half of which were closely associated with cancer initiation and progression; as well as a cancer-related network associated with miRNA target regulation. This novel approach provides information on miRNA target regulation on a genome-wide scale and supports the application of miRNA expression as a biomarker of carcinogenicity. This study is now available online at BMC Genomics
.
.For additional information, please contact Tao Chen, Ph.D., Division of Genetic and Molecular Toxicology, FDA/NCTR.
.png)
No hay comentarios:
Publicar un comentario